ATT-02 / Attivare Therapeutics - LARVOL DELTA

Attivare Therapeutics to Present Preclinical Data for ATT-01 and ATT-02 at the American Association for Cancer Research (AACR) Annual Meeting 2025 (Businesswire) - "Attivare Therapeutics, Inc...announced it will present preclinical data for its novel ATT-01 and ATT-02 therapeutics in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025. ATT-01 uses its ATTimmune platform technology, a silica-based, biodegradable scaffold (mesoporous silica rod, MSR), loaded with GM-CSF and CpG to induce differentiation of AML blasts in vitro, a significant vaccine-like T cell response, and durable remission in syngeneic murine models of AML. Intratumoral ATT-02 combines the ATTimmune scaffold coupled with Interleukin 12 (IL-12) to show potent anti-tumor immunity compared to IL-12 alone in multiple single tumor syngeneic models and abscopal syngeneic models. Complete responses were observed in two colon carcinoma models (localized and abscopal) after a single dose of ATT-02."

Preclinical • Acute Myelogenous Leukemia • Colon Cancer